we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot
Company profile
Ticker
CLPT
Exchange
Website
CEO
Joseph Michael Burnett
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MRI INTERVENTIONS, INC., SURGI VISION INC, SURGIVISION INC
SEC CIK
Corporate docs
Subsidiaries
ClearPoint Neuro (Canada) Inc. • ClearPoint Neuro UK Ltd • ClearPoint Neuro Germany GmbH. • ClearPoint Neuro Italy, S.r.l. ...
IRS number
582394628
CLPT stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
5 Apr 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
12 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
424B2
Prospectus for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue
8 Jan 24
EFFECT
Notice of effectiveness
21 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
Transcripts
CLPT
Earnings call transcript
2023 Q4
12 Mar 24
CLPT
Earnings call transcript
2023 Q3
9 Nov 23
CLPT
Earnings call transcript
2023 Q2
8 Aug 23
CLPT
Earnings call transcript
2023 Q1
11 May 23
CLPT
Earnings call transcript
2022 Q4
1 Mar 23
CLPT
Earnings call transcript
2022 Q3
8 Nov 22
CLPT
Earnings call transcript
2022 Q2
9 Aug 22
CLPT
Earnings call transcript
2022 Q1
12 May 22
CLPT
Earnings call transcript
2021 Q4
2 Mar 22
CLPT
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.34 mm | 24.34 mm | 24.34 mm | 24.34 mm | 24.34 mm | 24.34 mm |
Cash burn (monthly) | 707.33 k | (no burn) | 1.63 mm | 1.85 mm | 598.67 k | 1.30 mm |
Cash used (since last report) | 4.71 mm | n/a | 10.86 mm | 12.32 mm | 3.98 mm | 8.68 mm |
Cash remaining | 19.64 mm | n/a | 13.48 mm | 12.03 mm | 20.36 mm | 15.66 mm |
Runway (months of cash) | 27.8 | n/a | 8.3 | 6.5 | 34.0 | 12.0 |
Institutional ownership, Q1 2023
13.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 78.90 mm |
Total shares | 3.62 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PTCT PTC Therapeutics | 2.96 mm | $71.54 mm |
Bigger Capital Fund L P | 655.69 k | $7.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Linda M. Liau | Common Stock | Grant | Acquire A | No | No | 6.8 | 436 | 2.96 k | 13,131 |
1 Apr 24 | Fletcher R John | Common Stock | Grant | Acquire A | No | No | 6.8 | 850 | 5.78 k | 74,797 |
1 Apr 24 | Girin Pascal E R | Common Stock | Grant | Acquire A | No | No | 6.8 | 1,056 | 7.18 k | 55,044 |
1 Apr 24 | Richards Timothy T. | Common Stock | Grant | Acquire A | No | No | 6.8 | 1,640 | 11.15 k | 44,408 |
11 Mar 24 | L. Jeremy Stigall | RSU Common Stock | Grant | Acquire A | No | No | 0 | 16,583 | 0.00 | 16,583 |
News
ClearPoint Neuro Congratulates Its Partner AviadoBio On First Patient Treated In Its ASPIRE-FTD Clinical Trial Evaluating AVB-101 For Frontotemporal Dementia With GRN Mutations
16 Apr 24
ClearPoint Neuro Congratulates Its Partner PTC Therapeutics On Completion Of Biologics License Application Submission To FDA For Upstaza As A Treatment For AADC Deficiency
19 Mar 24
Stifel Reiterates Buy on ClearPoint Neuro, Raises Price Target to $9
13 Mar 24
ClearPoint Neuro: Q4 Earnings Insights
12 Mar 24
ClearPoint Neuro Q4 2023 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $6.810M Beat $6.533M Estimate
12 Mar 24
Press releases
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
16 Apr 24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
8 Apr 24
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
19 Mar 24
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
1 Mar 24
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
28 Feb 24